What were Gland Pharma's consolidated net profit and revenue for the quarter ended June 30, and how did they compare to year-ago figures and analyst estimates?

Gland Pharma reported a consolidated net profit of 3.17 billion rupees ($33.3 million) for the quarter ended June 30, up from 2.15 billion rupees a year earlier, and beating analysts' average estimate of 2.89 billion rupees; overall revenue rose 20% to 18 billion rupees, also surpassing the estimated 17.33 billion rupees.

How did Gland Pharma's U.S. and European sales perform in the first quarter, and what was their relative contribution to total sales?

U.S. sales — which make up more than half of the company's total — rose 32%, while Europe business posted a 20% rise; this strong performance in both key markets drove the overall results, following recovery in production at its Cenexi units in France and Belgium in late 2025 after prior disruptions had hurt results for most of last year.

India's Gland Pharma beats quarterly profit view on strong Europe, US sales

Aug 10, 2026

India's Gland Pharma beat quarterly profit estimates with a $33.3 million net profit, driven by 32% U.S. and 20% European sales growth. Recovery at its Cenexi production units in France and Belgium supported the revenue rise.

reuters

2026-05-17

Indian Shares Join Asian Slump as US-Iran Stalemate Continues

2026-06-11

Reliance, Vedanta, Adani Join India's Drive to Cut China Rare Earth Dependence, Sources Say

2026-08-10

India's Gland Pharma beats quarterly profit view on strong Europe, US sales

India's Gland Pharma beats quarterly profit view on strong Europe, US sales

FAQ